Companies Dominating the Heparin-induced Thrombocytopenia Landscape
- Endo International plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- PlateletBio
- AUROMEDICS PHARMA LLC
- Fresenius Kabi USA
- Pfizer Inc
- Caplin Steriles Ltd
- Hikma Pharmaceuticals PLC
- Teva Pharmaceuticals Industries Limited
- NOVARTIS AG
- Eagle Pharmaceutical Inc
- WEST WARD INC
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of heparinâ€induced thrombocytopenia is evaluated at USD 10.79 billion.
The heparinâ€induced thrombocytopenia market size was valued at USD 10.37 billion in 2024 and is set to exceed USD 19.08 billion by 2037, expanding at over 4.8% CAGR during the forecast period i.e., between 2025-2037. Presence of advanced diagnostic tools will fuel the market growth.
North America industry is likely to account for largest revenue share of 33% by 2037, due to rising prevalence of heparin-induced thrombocytopenia in the region.
The major players in the market are Pfizer Inc, Caplin Steriles Ltd, Hikma Pharmaceuticals PLC, Teva Pharmaceuticals Industries Limited, NOVARTIS AG, Eagle Pharmaceutical Inc., WEST WARD INC, and others.
